HPV status to predict outcome for anal cancer treated with radiochemotherapy

Autor:	Martine Ottstadt, Miriam Reuschenbach, Grit Welzel, Frederik Wenz, Nicolas Wentzensen, S. Mai, Marcus J. Trunk, Frank Lohr, Magnus von Knebel Doeberitz
Rok vydání:	2013
Předmět:	Gynecology Oncology Cancer Research medicine.medical_specialty business.industry Internal medicine medicine HPV infection Anal cancer medicine.disease business Hpv status
Zdroj:	Journal of Clinical Oncology. 31:4065-4065
ISSN:	1527-7755 0732-183X
Popis:	4065 Background: Evaluation of the HPV infection- and transformation-status as a predictor of the response to definitive radio-chemotherapy for anal cancer. Methods: 80 patients (54 fm, 26 m) with histologically confirmed anal cancer and known HPV-Infection- (determined by PCR) and p16-expression-status (determined by immunohistochemistry) were analyzed. All pts. were treated with definitive radio-chemotherapy (RCT) with 5-FU/MMC, median age 60ys (35–86), median follow up 54mo (4–180). 41 pts. were HPV+ and p16+ (group 1), 10 pts. were HPV-/p16+ (group 2), 9 pts. were HPV+/p16- (group 3) and 17 pts. were HPV+/p16- (group 4). Endpoints were local control (LC) at 5ys and overall survival (OS) at 5ys. In addition to HPV/p16 status, the influence of T-stage and tumor localization (canal vs. margin) was analyzed. Results: More women than men were HPV+ (fm 77% vs. m 33%) while gender was evenly distributed among HPV-pts. (fm 48% vs. m 53%). Upon univariate analysis, gender, HPV+ and p16+ were significant predictors of both LC and OS (p
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ff39ed0d1e42f417919f2137c3d74e4f https://doi.org/10.1200/jco.2013.31.15_suppl.4065 Zobrazit plný text záznamu